PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Aficamten→

Aficamten PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
2364554-48-1
Molecular formula
C18H19N5O2
Molecular weight
337.4 g/mol
Drug class
Cardiac myosin inhibitorallosteric, reversible sarcomere modulator
Mechanism of action
Allosterically and reversibly inhibits cardiac myosin motor activity, reducing force generation at the cardiac sarcomere. This decreases myocardial contractility and left-ventricular outflow-tract obstruction in hypertrophic cardiomyopathy.
Indications / reported uses
  • Treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and symptoms under the US FDA indication; requires product-specific echocardiographic monitoring and risk controls

Sources: US FDA — Drug Trials Snapshot: MYQORZO (approval 19 Dec 2025) · NLM DailyMed — MYQORZO prescribing information · FDA product information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Aficamten PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Aficamten Permitted Daily Exposure (PDE) report (the Aficamten PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Aficamten Occupational Exposure Limit (OEL) report (the Aficamten OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.